SCHEMBL9008000

SCHEMBL9008000

COc1ccc(Cn2c(NCCn3c(N)nc4ccccc43)nc(=O)n(Cc3ccc(F)cc3)c2=O)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PROKR1 Q8TCW9 15/20 0.62
KCNH2 Q12809 2/20 0.59
PROKR2 Q8NFJ6 2/20 0.56
SSTR5 P35346 2/20 0.49
MEN1 O00255 1/20 0.48
MLNR O43193 1/20 0.48
CACNA1F O60840 1/20 0.48
EED O75530 1/20 0.48
USP2 O75604 1/20 0.48
ABCB11 O95342 1/20 0.48
EGFR P00533 1/20 0.48
LMNA P02545 1/20 0.48
HLA-A P04439 1/20 0.48
ERBB2 P04626 1/20 0.48
TP53 P04637 1/20 0.48
CYP1A2 P05177 1/20 0.48
LCK P06239 1/20 0.48
FYN P06241 1/20 0.48
CHRM2 P08172 1/20 0.48
CHRM4 P08173 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3655258 0.90 KCNH2 (0.62) PROKR1KCNH2PROKR2SSTR5MEN1
SCHEMBL13801510 0.89 PROKR1 (0.59) PROKR1KCNH2PROKR2
SCHEMBL3654469 0.89 PROKR1 (0.59) PROKR1KCNH2PROKR2SSTR5MEN1
SCHEMBL326449 0.81 PROKR1 (0.82) PROKR1PROKR2MEN1USP2MAPT
SCHEMBL13801512 0.81 PROKR1 (0.64) PROKR1PROKR2MEN1USP2MAPT
SCHEMBL3652312 0.78 PROKR1 (0.57) PROKR1KCNH2PROKR2
SCHEMBL5960121 0.77 PROKR1 (0.73) PROKR1PROKR2
SCHEMBL2302207 0.76 HTT (0.71) LMNATP53GAAMAPTHTT
SCHEMBL8528608 0.75 PROKR1 (0.74) PROKR1PROKR2
SCHEMBL325742 0.75 PROKR1 (0.68) PROKR1PROKR2MEN1USP2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140038968-A1 AMINO-HETEROARYL-CONTAINING PROKINETICIN 1 RECEPTOR ANTAGONISTS COATS STEVEN J (US) 2014-02-06 US disclosed
US-20140038968-A1 AMINO-HETEROARYL-CONTAINING PROKINETICIN 1 RECEPTOR ANTAGONISTS COATS STEVEN J (US) 2014-02-06 US disclosed
US-8324380-B2 Amino-heteroaryl-containing prokineticin 1 receptor antagonists JANSSEN PHARMACEUTICA NV (BE) 2012-12-04 US disclosed
US-8324380-B2 Amino-heteroaryl-containing prokineticin 1 receptor antagonists JANSSEN PHARMACEUTICA NV (BE) 2012-12-04 US disclosed
US-20120245077-A1 PROKINETICIN 1 RECEPTOR MABUS JOHN R (US) 2012-09-27 US disclosed
US-20120245077-A1 PROKINETICIN 1 RECEPTOR MABUS JOHN R (US) 2012-09-27 US disclosed
US-8188081-B2 Methods of treating inflammation using prokineticin 1 receptor antagonists JANSSEN PHARMACEUTICA, NV (BE) 2012-05-29 US disclosed
US-8188081-B2 Methods of treating inflammation using prokineticin 1 receptor antagonists JANSSEN PHARMACEUTICA, NV (BE) 2012-05-29 US disclosed
US-20110136811-A1 PROKINETICIN 1 RECEPTOR MABUS JOHN R 2011-06-09 US disclosed
US-20110136811-A1 PROKINETICIN 1 RECEPTOR MABUS JOHN R 2011-06-09 US disclosed
US-7825117-B2 Methods of modulating intestine epithelial functions JANSSEN PHARMACEUTICA NV (BE) 2010-11-02 US disclosed
US-7825117-B2 Methods of modulating intestine epithelial functions JANSSEN PHARMACEUTICA NV (BE) 2010-11-02 US disclosed
US-20090163505-A1 AMINO-HETEROARYL-CONTAINING PROKINETICIN 1 RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2009-06-25 US disclosed
US-20090163505-A1 AMINO-HETEROARYL-CONTAINING PROKINETICIN 1 RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2009-06-25 US disclosed
WO-2009058653-A1 AMINO-HETEROARYL-CONTAINING PROKINETICIN 1 RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA N.V. (BE) 2009-05-07 WO disclosed
US-20070021422-A1 Prokineticin 1 receptor JANSSEN PHARMACEUTICA NV (BE) 2007-01-25 US disclosed
US-20070021422-A1 Prokineticin 1 receptor JANSSEN PHARMACEUTICA NV (BE) 2007-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140038968-A1 AMINO-HETEROARYL-CONTAINING PROKINETICIN 1 RECEPTOR ANTAGONISTS PROKR1, PROKR2, GIPR PROKR1 1/4885KCNH2 3165/4885PROKR2 2/4885
US-20110136811-A1 PROKINETICIN 1 RECEPTOR PROKR1, PROKR2, GIPR PROKR1 1/4885KCNH2 1016/4885PROKR2 2/4885
US-20070021422-A1 Prokineticin 1 receptor PROKR1, PROKR2, GIPR PROKR1 1/4885KCNH2 1016/4885PROKR2 2/4885
US-20120245077-A1 PROKINETICIN 1 RECEPTOR PROKR1, PROKR2, GIPR PROKR1 1/4885KCNH2 1016/4885PROKR2 2/4885
US-20090163505-A1 AMINO-HETEROARYL-CONTAINING PROKINETICIN 1 RECEPTOR ANTAGONISTS PROKR1, PROKR2, GIPR PROKR1 1/4885KCNH2 3165/4885PROKR2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.